Advertisement
ALNY or BNTX or VRTX
Alnylam Pharmaceuticals (ALNY) vs BioNTech (BNTX) vs Vertex Pharmaceuticals (VRTX) Earnings Recap: Recent Results and Biotech Momentum
Key Takeaways
- BioNTech (BNTX) released Q4 and full-year 2025 earnings on March 10, 2026, reporting €907.4 million in quarterly revenue (down YoY due to lower COVID-19 vaccine sales) and full-year revenue of €2.9 billion, with adjusted net loss of €117 million.
- Alnylam (ALNY) Q4 2025 results on February 12, 2026, showed $1.1 billion revenue (up 85% YoY), non-GAAP EPS of $1.25 (beat estimates), driven by 151% TTR franchise growth from AMVUTTRA.
- Vertex (VRTX) Q4 2025 on February 12, 2026, delivered $3.19 billion revenue (up 10% YoY), non-GAAP EPS $5.03, with full-year revenue of $12 billion (up 9%), led by CF franchise.
- All three biotechs demonstrated revenue growth in FY 2025, with ALNY and VRTX achieving profitability; BNTX holds €17.2 billion cash for oncology pivot.
Earnings Context and Competitive Landscape
These companies operate in biotech, focusing on genetic diseases and oncology. Alnylam (ALNY) leads in RNAi therapeutics for rare diseases like ATTR amyloidosis. BioNTech (BNTX) transitions from COVID-19 vaccines to immuno-oncology. Vertex (VRTX) dominates cystic fibrosis with a growing non-CF portfolio including CASGEVY. Recent Q4/FY 2025 earnings highlight revenue resilience amid pipeline investments, with competition in gene silencing and mRNA tech driving innovation overlap.
BioNTech Focus
BioNTech (BNTX) reported Q4 2025 revenues of €907.4 million on March 10, 2026, down from €1,190 million YoY due to normalized COVID-19 vaccine demand, offset by BMS collaboration. Full-year 2025 revenues reached €2.87 billion, up slightly YoY. Adjusted diluted loss per share was €0.33 in Q4 (GAAP €1.25 loss), with full-year adjusted net loss €117 million (€0.48/share). Cash position: €17.2 billion. FY 2026 guidance: €2.0-2.3 billion revenue, higher R&D at €2.2-2.5 billion. Strategic focus on late-stage oncology like pumitumag.
Alnylam Pharmaceuticals Context
Alnylam (ALNY) posted Q4 2025 total revenues of $1.097 billion on February 12, 2026 (up 85% YoY), with net product revenues at $994.7 million driven by AMVUTTRA ($827 million, +121% YoY). Non-GAAP diluted EPS $1.25 beat estimates; full-year revenues $3.71 billion (up 65%). FY 2026 net product guidance: $4.9-5.3 billion. Strong TTR growth (151% Q4) positions ALNY for sustained rare disease leadership.
Vertex Pharmaceuticals Context
Vertex (VRTX) reported Q4 2025 total revenues of $3.19 billion on February 12, 2026 (up 10% YoY), U.S. up 12% to $2.06 billion on CF demand and new launches. Non-GAAP EPS $5.03 (up 26% YoY); full-year revenues $12 billion (up 9%), CF franchise +7%. CASGEVY Q4 revenue $54 million. Cash: $12.3 billion. Pipeline advances in pain, kidney disease bolster diversification.
Head-to-Head Earnings and Market Comparison
ALNY showed highest growth (Q4 revenue +85%, FY +65%) with profitability inflection. VRTX delivered scale ($12B FY revenue, consistent EPS beats) and margin strength. BNTX faced vaccine headwinds but boasts unmatched cash (€17.2B) for oncology risks. Growth signals favor ALNY's TTR surge; VRTX exhibits lowest risk via CF dominance; sentiment tilts to VRTX for execution, ALNY for upside.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the strongest AI bots from a larger pool of hundreds of bots trading thousands of tickers. It ranks them by recent performance across various timeframes, including short-term signals (1 day to 1 week), medium-term patterns (1-6 months), and long-term strategies (6-12 months). Bots vary by style—momentum, mean reversion, scalping, or swing trading—with metrics like win rate, profit factor, Sharpe ratio, and max drawdown. Users can filter by asset class, risk level, or popularity to deploy top performers for automated trading signals on stocks like ALNY, BNTX, and VRTX. Updated real-time, it empowers data-driven decisions without emotional bias.
Tickeron AI Verdict
Tickeron AI favors VRTX with 65% probability over the next quarter due to proven revenue scale ($12B FY), CF moat, and pipeline diversification yielding consistent profitability (non-GAAP EPS $18.40 FY). ALNY's hypergrowth (TTR +151%) offers 20% upside potential but higher volatility; BNTX's cash hoard mitigates oncology risks (15% chance) amid vaccine decline.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALNY’s FA Score shows that 1 FA rating(s) are green whileBNTX’s FA Score has 2 green FA rating(s), and VRTX’s FA Score reflects 0 green FA rating(s).
- ALNY’s FA Score: 1 green, 4 red.
- BNTX’s FA Score: 2 green, 3 red.
- VRTX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALNY’s TA Score shows that 2 TA indicator(s) are bullish while BNTX’s TA Score has 4 bullish TA indicator(s), and VRTX’s TA Score reflects 4 bullish TA indicator(s).
- ALNY’s TA Score: 2 bullish, 7 bearish.
- BNTX’s TA Score: 4 bullish, 6 bearish.
- VRTX’s TA Score: 4 bullish, 4 bearish.
Price Growth
ALNY (@Biotechnology) experienced а -3.87% price change this week, while BNTX (@Biotechnology) price change was +7.77% , and VRTX (@Biotechnology) price fluctuated +1.13% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.61%. For the same industry, the average monthly price growth was +9.02%, and the average quarterly price growth was +11.47%.
Reported Earning Dates
ALNY is expected to report earnings on Apr 30, 2026.
BNTX is expected to report earnings on May 11, 2026.
VRTX is expected to report earnings on May 04, 2026.
Industries' Descriptions
@Biotechnology (+7.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| ALNY | BNTX | VRTX | |
| Capitalization | 41.3B | 26B | 112B |
| EBITDA | 631M | 171M | 4.87B |
| Gain YTD | -22.127 | 8.109 | -2.682 |
| P/E Ratio | 132.90 | 161.76 | 28.80 |
| Revenue | 3.71B | 3.15B | 12B |
| Total Cash | 2.91B | 14.5B | 6.61B |
| Total Debt | 1.28B | 245M | 2.03B |
ALNY | BNTX | VRTX | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 13 | 14 | 16 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 94 Overvalued | 4 Undervalued | 80 Overvalued | |
PROFIT vs RISK RATING 1..100 | 53 | 100 | 35 | |
SMR RATING 1..100 | 15 | 91 | 40 | |
PRICE GROWTH RATING 1..100 | 62 | 52 | 59 | |
P/E GROWTH RATING 1..100 | 100 | 1 | 53 | |
SEASONALITY SCORE 1..100 | 50 | 42 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BNTX's Valuation (4) in the null industry is significantly better than the same rating for VRTX (80) in the Biotechnology industry, and is significantly better than the same rating for ALNY (94) in the Biotechnology industry. This means that BNTX's stock grew significantly faster than VRTX’s and significantly faster than ALNY’s over the last 12 months.
VRTX's Profit vs Risk Rating (35) in the Biotechnology industry is in the same range as ALNY (53) in the Biotechnology industry, and is somewhat better than the same rating for BNTX (100) in the null industry. This means that VRTX's stock grew similarly to ALNY’s and somewhat faster than BNTX’s over the last 12 months.
ALNY's SMR Rating (15) in the Biotechnology industry is in the same range as VRTX (40) in the Biotechnology industry, and is significantly better than the same rating for BNTX (91) in the null industry. This means that ALNY's stock grew similarly to VRTX’s and significantly faster than BNTX’s over the last 12 months.
BNTX's Price Growth Rating (52) in the null industry is in the same range as VRTX (59) in the Biotechnology industry, and is in the same range as ALNY (62) in the Biotechnology industry. This means that BNTX's stock grew similarly to VRTX’s and similarly to ALNY’s over the last 12 months.
BNTX's P/E Growth Rating (1) in the null industry is somewhat better than the same rating for VRTX (53) in the Biotechnology industry, and is significantly better than the same rating for ALNY (100) in the Biotechnology industry. This means that BNTX's stock grew somewhat faster than VRTX’s and significantly faster than ALNY’s over the last 12 months.
| ALNY | BNTX | VRTX | |
|---|---|---|---|
| RSI ODDS (%) | N/A | 3 days ago 85% | N/A |
| Stochastic ODDS (%) | 3 days ago 63% | 3 days ago 80% | 3 days ago 64% |
| Momentum ODDS (%) | 3 days ago 65% | 3 days ago 74% | 3 days ago 64% |
| MACD ODDS (%) | 3 days ago 72% | 3 days ago 76% | 3 days ago 62% |
| TrendWeek ODDS (%) | 3 days ago 64% | 3 days ago 68% | 3 days ago 62% |
| TrendMonth ODDS (%) | 3 days ago 69% | 3 days ago 69% | 3 days ago 36% |
| Advances ODDS (%) | 6 days ago 76% | 3 days ago 70% | 6 days ago 63% |
| Declines ODDS (%) | 3 days ago 66% | 21 days ago 80% | 4 days ago 43% |
| BollingerBands ODDS (%) | 3 days ago 87% | 3 days ago 79% | N/A |
| Aroon ODDS (%) | 3 days ago 71% | 3 days ago 85% | 3 days ago 30% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| GOEX | 93.42 | 2.34 | +2.57% |
| Global X Gold Explorers ETF | |||
| VHT | 278.45 | 4.16 | +1.52% |
| Vanguard Health Care ETF | |||
| BOE | 11.77 | 0.06 | +0.51% |
| BlackRock Enhanced Global Dividend Trust | |||
| PMIO | 50.98 | 0.17 | +0.32% |
| PGIM Municipal Income Opportunities ETF | |||
| AMZD | 9.12 | -0.01 | -0.13% |
| Direxion Daily AMZN Bear 1X ETF | |||
BNTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BNTX has been loosely correlated with MRNA. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if BNTX jumps, then MRNA could also see price increases.
| Ticker / NAME | Correlation To BNTX | 1D Price Change % | ||
|---|---|---|---|---|
| BNTX | 100% | +0.78% | ||
| MRNA - BNTX | 49% Loosely correlated | -1.76% | ||
| SMMT - BNTX | 49% Loosely correlated | +2.99% | ||
| KYMR - BNTX | 44% Loosely correlated | +1.82% | ||
| PCVX - BNTX | 43% Loosely correlated | +0.24% | ||
| AXON - BNTX | 43% Loosely correlated | +2.49% | ||
More | ||||